William Blair downgraded Icosavax (ICVX) to Market Perform from Outperform, calling the company’s agreement to be acquired by AstraZeneca (AZN) a “successful exit.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICVX:
- M & A News: AstraZeneca’s (NASDAQ:AZN) $1.1B Bet on ICVX Sends Shares Soaring
- Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
- Icosavax initiated with a Buy at Guggenheim
- Icosavax reports Q3 EPS (44c), consensus (57c)
- Icosavax, Inc. (ICVX) Q3 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue